Protecting the integrity of neurons in the brain to
maintain quality of life
NeuroTau, Inc. is a biotech company, formed in 2017, that focuses on developing drugs that target the disruption or decay of the important neurobiological protein called Tau, and other important and associated proteins like amyloid and processes to reduce harmful inflammation that can lead to many serious diseases with significant unmet medical needs.
Our development programs are primarily focused on neurodegenerative & neuromuscular diseases including: Progressive Supranuclear Palsy, Frontotemporal Dementia, Alzheimer’s Disease, Traumatic Brain Injury, PTSD, Down’s syndrome, and Parkinson Disease.
On-going research has linked these diseases to various malfunctions of tau, amyloid and inflammation within the brain. By correcting them, NeuroTau aims at opening the way for a broad range of disease modifying mechanism-based therapies.
NeuroTau is led by a team of scientific, clinical and industry executives with over 75-years of combined experience and a passion to bring forward breakthrough drug therapies for a host of brain-related diseases.
“People with tau diseases have a wide range of symptoms because basically, wherever tau is aggregating, those parts of the brain are degenerating” David Holtzman, MD, the Andrew B. and Gretchen P. Jones Professor and head of the Department of Neurology at Washington University School of Medicine in St. Louis.